May 9, 2024

Has Spring Sprouted New Growth in Immuno-Oncology?

As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days...

by Jonathan Montagu
Read more
July 11, 2023

On the Road at ASCO 2023: Key Takeaways, Observations and Reflections

The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. The meeting...

by Amanda Redig
Read more
March 1, 2023

Build It and They Will Come – New Review Spotlights the Scientific Momentum Building for CBL-B Inhibition

The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...

by Jonathan Montagu
Read more
A young girl hugging her mother from behind
January 4, 2023

Reimagining I-O with Our First Investigational Drug and a New Approach to Clinical Discovery

HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor...

by Jonathan Montagu
Read more
Wrecking ball destroying cancer cell
July 13, 2021

Immuno-Oncology: The Comeback Kid

Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011…

by Tim Reilly
Read more